Another study, by Xia et al., evaluated the association between patient response and baseline levels of circulating B cells in patients with NSCLC who were treated with anti-PD-1 (n = 120) or anti-PD-L1 (n = 30) [77]. Here, CD274 is linked to non-small cell lung carcinoma.